MAIA Biotechnology, Inc. (MAIA) has shared an update.
MAIA Biotechnology, Inc. has announced promising results from its Phase 2 THIO-101 clinical trial in a poster and supporting presentation, both showcasing the potential of THIO in treating advanced non-small cell lung cancer alongside the drug cemiplimimab. Released during the ASCO 2024 Annual Meeting and on the company’s website, these materials highlight the progress for patients who have not responded to traditional therapies. However, the company cautions that these forward-looking statements shouldn’t be relied upon too heavily, as they may not be updated and are not filed under SEC regulations.
See more data about MAIA stock on TipRanks’ Stock Analysis page.
